Molecular and cell biologists at the University of Virginia Health System have discovered new information about how the Ebola virus works that could eventually lead to new drug treatments for the deadly virus.
No known cure exists for the Ebola virus, which causes hemorrhagic fever and can be fatal in up to 90 percent of cases. People who are infected can have extensive bleeding in and from the body but usually die of shock, according to the National Institutes of Health. The disease has only been detected among people living in parts of Africa, but there are concerns Ebola could be used as a bioterrorism agent.
UVAs researchers focused on how the Ebola virus enters healthy cells. "What we discovered is a very important piece of the Ebola virus life cycle. We found a key that opens the cellular lock which, in turn, lets the virus in," explains Lukas Tamm, PhD, the Harrison Distinguished Professor of Molecular Physiology and Biological Physics and director of UVAs Center for Membrane Biology.
The UVA team found out how a critical piece of the glycoprotein that sits on the surface of the Ebola virus, called the fusion loop, is responsible for the penetration of the virus into a healthy cell. The fusion loop changes its structure to allow Ebola to enter the cell in a process called membrane fusion, which Tamm likened to the clenching of a fist. The front end of the fusion loop punches a hole into the healthy cell membrane, connecting or fusing the two membranes.
"Ebola has to get into the cell in a controlled way, make thousands of copies of itself, spread into other cells and then do its damage," Tamm says. "But now that we have images of these molecules, we could design drugs that better target Ebola. Thats the hope here, although there are still many hurdles to overcome before this basic science discovery can be translated into treatments for patients."
The research performed in collaboration with the lab of Judith White, PhD, a UVA professor of cell biology was done on a $2 million nuclear magnetic resonance spectroscopy instrument bought by UVA through a shared-instrumentation grant from the National Institutes of Health.
Their findings were published online June 20 in the journal Proceedings of the National Academy of Sciences (PNAS). The paper, titled "Structure and function of the complete internal fusion loop from Ebolavirus glycroprotein 2," can be found at the journals website.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.